Search
Now showing items 1-4 of 4
Marked neutropenia: Significant but rare in people with multiple sclerosis after alemtuzumab treatment.
(2017-11)
BACKGROUND: Alemtuzumab is a CD52-specific monoclonal antibody that markedly depletes T and B lymphocytes and inhibits relapsing multiple sclerosis (MS). However, polymorphonuclear neutrophils also express CD52 and can be ...
Validation of an environmentally-friendly and affordable cardboard 9-hole peg test.
(2017-10)
BACKGROUND: In multiple sclerosis (MS) upper limb neurological impairments, are an important driver of disability and handicap. The gold standard for assessing upper limb function is the 9-hole peg test (9HPT). One ...
Severe lymphopenia after subcutaneous cladribine in a patient with multiple sclerosis: To vaccinate or not?
(2020-10-09)
Objective: To describe a fatal case of influenza A pneumonia in a patient with severe lymphopenia after receiving subcutaneous cladribine to treat her multiple sclerosis (MS). Methods: Case report. Results: A 53-year-old ...
Organic solvents and Multiple Sclerosis: the doubled risk dilemma.
(2023-09-29)
BACKGROUND: Compensation for industrial disease in the UK may be obtained in two ways. A State scheme includes a list of accepted associations between occupations and diseases with evidence of a causative association. ...